Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea

NCT06011954 is registered in ClinicalTrials.gov with Astellas Pharma Korea, Inc. as lead sponsor.

NCT NCT06011954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06011954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea
Lead sponsor
Astellas Pharma Korea, Inc.
Phase
Observational
Overall status
Recruiting
Start date
November 1, 2023
Completion date
July 31, 2027
Enrollment
202 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial cancer